DOvEEgene - Detecting Ovarian and Endometrial Cancer Early Using Genomics - is a research test available to women between the ages of 45 and 75 who have not previously had surgery to remove their uterus. This research project was awarded a grant from Genome Canada and Genome Quebec in collaboration with the MUHC Foundation (Genomic Applications Partnership Program) to initiate final testing phase. The study is led by Dr. Lucy Gilbert, the Director of the Gynecology-Oncology Division at Montreal's Royal Victoria Hospital, Glen Site.
In the previous phase of the study, the DOvEEgene test was able to detect ovarian and/or endometrial cancer as early as stage 1 versus stage 3 or 4 with current methods. Early diagnosis is crucial because when ovarian cancer is diagnosed in its early stage, the survival rate is 93% versus 10-30% in advance stage (5 years survival rate means the percentage of women alive 5 years after initial diagnosis).
All women, symptomatic or asymptomatic, between the ages of 45 and 75 who have a uterus are eligible to participate in the DOvEEgene research study. The medical examinations and services are free for residents of Quebec with a valid RAMQ card as they are covered by the Régie de l'Assurance Maladie du Québec (RAMQ).
To learn more about the DOvEEgene study, eligibility, and to book an appointment, please visit https://doveegene.com/
In addition, you are most welcome to spread this news about the DOvEEgene clinic at the QEHC - increasing awareness of this great initiative can save lives.